

Recommendations of the SEC meeting to examine COVID-19 related proposal under accelerated approval process made in its 184rd meeting held on 21.09.2021 at CDSCO, HQ New Delhi:

Agenda No	File Name & Drug Name, Strength	Firm Name	Recommendation
SND Division			
1.	SND/CT/21/000035 Favipiravir 200/800 mg tablet	M/s Mylan	<p>The firm has presented the Phase IV clinical trial protocol of Favipiravir 200/800 mg tablet before the committee for approval.</p> <p>After detailed deliberation, the committee recommended for grant of permission for conduct of the Phase IV clinical trial as per the protocol presented.</p>